Moleculent Secures $20 Million to Advance Cell Communication Mapping Technology
核心洞察
Moleculent AB (搜索) closed a $20 million financing round led by Rubicon Healthcare Partners (搜索) to scale its functional profiling platform that maps cell-cell communication (搜索) in human tissue.
The technology uses proprietary Proximity Ligation Assay to detect cell interactions in their native environment, addressing a critical gap in understanding how cells communicate within tissues.
Strong demand from research institutions and pharmaceutical partners across Europe and the US has prompted expansion of the company's Techstart Early Access Program.
Moleculent AB (搜索), a Stockholm-based life sciences technology company, has secured $20 million in Series funding to advance its pioneering functional profiling platform that maps cell-cell communication (搜索) at scale in human tissue. The financing round was led by Rubicon Healthcare Partners (搜索), with participation from ARCH Venture Partners (搜索), Eir Ventures (搜索), and other existing investors.
The funding comes as the company experiences surging demand from leading research institutions and pharmaceutical partners across Europe and the United States for its category-defining technology. "The market is telling us it's ready," said Olle Ericsson, PhD, Co-Founder and CEO of Moleculent. "We are seeing surging demand from leading research institutions and pharmaceutical partners across both Europe and the US."
Breakthrough Technology Addresses Critical Research Gap
Moleculent's platform addresses a fundamental limitation in current research capabilities. As Nigel Jamieson, Professor of Pancreatic and Liver Surgery at the University of Glasgow and an inaugural Techstart partner, explained: "For years, we've been able to see where cells are and what they express, but we couldn't see how they actually talk to each other in the tissue. Moleculent changes that completely—this is the kind of tool that reshapes entire research programs."
The technology is built on Moleculent's proprietary Proximity Ligation Assay, which detects cell-cell interactions in their native environment at high-plex. The platform simultaneously enables cell typing through the detection of individual proteins to provide tissue context, offering researchers unprecedented insight into cellular complexity and disease mechanisms.
Strategic Leadership and Commercial Expansion
As part of the financing, Ole Dahlberg, Managing Partner at Rubicon Healthcare Partners (搜索), has joined Moleculent's Board of Directors. Dahlberg brings more than 20 years of international management experience in the life sciences, having held leadership roles at Life Technologies (搜索), Qiagen, and Thermo Fisher Scientific (搜索), where he previously led Cell Biology and Sample Preparation.
"We have evaluated platforms across the life sciences tools landscape for years, and Moleculent stands out as truly category-defining," said Dahlberg. "The company's approach to directly mapping cell-cell communication (搜索) has the potential to transform how researchers study disease and develop therapies."
Accelerated Market Access Through Early Access Program
The new capital will support the expansion of Moleculent's Techstart Early Access Program, which provides select academic and biopharma partners priority access to the platform ahead of commercial launch. The company is developing an automated instrument designed to enable large-scale studies with high reproducibility and minimal hands-on time, making the technology accessible to translational labs globally.
The funding will also accelerate Moleculent's commercial operations in the United States and drive the commercial launch of the instrument. With backing from specialist life sciences investors including ARCH Venture Partners (搜索), Rubicon Healthcare Partners (搜索), and Eir Ventures (搜索), the company is positioned to scale from breakthrough technology to global impact.